Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of XLF055 with metronidazole to prevent recurrent bacterial vaginosis
CTR20254340Phase 3Active
- Sponsor
- Zhejiang Xinlifei Biotechnology
- Start
- Jan 2026
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Bi-Live, metronidazole in bacterial vaginosis (BV), sponsored by Zhejiang Xinlifei Biotechnology. Started Jan 2026; status: active.
02
Drugs
Bi-Livemetronidazole
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on CTR20254340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254340.